Under the partnership, Lonza will offer cGMP drug product manufacturing services for clinical supply from its fill and finish site in Stein, Switzerland. Credit: Julia Koblitz on Unsplash.

French pharmaceutical group Pierre Fabre has signed a manufacturing agreement with Swiss manufacturing company for pharma, biotech and nutrition industries, Lonza, for W0180 antibody drug product. 

Discovered by Pierre Fabre, W0180 is a monoclonal antibody that acts on the V-domain Ig suppressor of T cell Activation (VISTA) checkpoint.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A negative checkpoint regulator of T cell response, VISTA is expressed within the tumour microenvironment, where its hindering can boost antitumor immune responses.

It is presently being analysed as monotherapy and along with pembrolizumab in a Phase I clinical trial for various solid tumours.

Under the partnership, Lonza will offer cGMP drug product (DP) manufacturing services for clinical supply from its fill and finish site in Stein, Switzerland.

See Also:

Pierre Fabre will utilise drug product capabilities and fill and finish expertise of Lonza.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ability of Lonza to offer manufacturing services and drug product development extends new solutions to customers and the potential to deliver quality products for use in clinical applications.

Pierre Fabre Medical Care CEO Jean-Luc Lowinski said: “We are delighted to entrust the production of the W0180 Drug Product to Lonza. Its Drug Product Services are well-suited for our innovative therapy manufacturing needs.

“W0180 will be manufactured in Lonza’s GS Xceed Expression CHO System, also successfully used for the IGF1R and cMet antibodies discovered by Pierre Fabre.”

In November last year, Pierre Fabre and Ribonexus entered an exclusive licence agreement on a series of the former’s patented small molecules that act on the Eukaryotic translation initiation factor 4A (eIF4A). 

This target is highly expressed in various solid and hematologic cancers, including melanoma, and is linked to resistance to various existing current therapies.